About Our Company
REACH is revolutionizing stroke rehabilitation with a personalized AI-powered therapeutic device that combines functional electrical stimulation (FES) and electromyography (EMG) to treat upper extremity disabilities.
Mission Statement
At REACH, we are dedicated to empowering stroke survivors and restoring their independence in everyday life by making recovery more accessible and more effective. REACH is a lifelong companion aimed to improve motor skills with personalized care and increase a patients quality of life.
The Problem
Stroke has become prevalent across the globe and developing medical
technology has increased the number of survivors living with disabilities due to stroke. An ever
growing population of stroke survivors requires medical device that can provide effective and
lasting care. In the chronic phase of stroke recovery, activity of daily living functionality steadily decreases
The American Stroke Association highlights "the important need for long-term adaptive healthcare".
The REACH Solution
Our device helps stroke survivors regain muscle control within the chronic phase of stroke., enabling them to perform their Activities of Daily Living. REACH is a wearable sleeve that supports muscle functionality in the foream allowing stroke survivors a greater abaility to perform activitites of daily living. By combining EMG, AI machine learning, and FES, REACH provides personalized and real-time support to stroke survivors, improving their quality of life.
Market Opprotunity
REACH's entry to market is the 2.6 million stroke patients with slight to moderate disability based on the Rankin Scale within the United States. There is a $104 million market for stroke rehabilitation devices which lead the development of our market profile.
Competitive Analysis
Competitors fail to provide personalized rehabilitation without frequent clinical visits. Their
costly, hard to use technology fails to enable patients to regain activities of daily living. Each device is unable to collect
muscle functionality data for accurate tracking by physicians, leading to static and manual rehabilitation.
*Note: Cionic comes in as our closest competitor but focuses on leg rehabilitation and not the forearm.
Pricing and Eligibility
REACH will have a $2200 downpayment and a $110 monthly subscription for continuous personalization and adapative care. Devices will be available for purchase through precription from your physician in the Fall of 2027.
Future Outlook
REACH is looking to fully launch in Quarter 1 of 2028. In the upcoming years we plan on completing testing and validation to obtain FDA approval. Manufacturing will start in the Fall 2027 in time for product launch in the next year.
Our Team
Our interdisciplinary team of dedicated engineers is working throughout the year to provide personalized and lasting care for stroke survivors.